<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00822809</url>
  </required_header>
  <id_info>
    <org_study_id>IP-CAT-AC-03</org_study_id>
    <nct_id>NCT00822809</nct_id>
  </id_info>
  <brief_title>CASIMAS: Catumaxomab Safety Phase IIIb Study With Intraperitoneal Infusion in Patients With Malignant Ascites Due to Epithelial Cancers</brief_title>
  <acronym>CASIMAS</acronym>
  <official_title>Two-arm, Randomized, Open-label, Phase IIIb Study Investigating the Safety of a 3 Hour i.p. Infusion of Catumaxomab With and Without Prednisolone Premedication in Patients With Malignant Ascites Due to Epithelial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neovii Biotech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neovii Biotech</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized phase IIIb study investigating the treatment of malignant ascites due to
      epithelial cancer (carcinomas) with the trifunctional antibody catumaxomab. In order to make
      the catumaxomab treatment more convenient for the patient and the hospital praxis the
      tolerability of 3 hour infusions of catumaxomab with and without premedication of
      prednisolone is evaluated.

      A total of 208 patients with malignant ascites due to epithelial cancer will be allocated to
      two treatment groups in a 1:1 ratio.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Safety data of the completed pivotal phase II/III trial, IP-REM-AC-01, in which catumaxomab
      was administered as 6 hour i.p. infusion showed that most reported AEs were cytokine
      release-related symptoms such as fever, nausea, and vomiting (based on the pharmacodynamic
      mode of action of catumaxomab) and abdominal pain. In order to make the catumaxomab treatment
      more convenient for the patient and the hospital praxis the current trial was designed to
      determine whether tolerability of the 3 hour infusion of catumaxomab with and without
      premedication of prednisolone. Prednisolone was chosen as additional premedication with the
      objective to reduce cytokine release related symptoms which might change with the switch from
      6 to 3 h infusion time.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Influence of prednisolone on the safety of 3 hours i.p. infusion of catumaxomab measured by a composite safety score</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Puncture-free survival defined as the time from clock start to first need for therapeutic ascites puncture or death, whichever occurs first.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety measured by • Incidence of all AEs, • Changes in clinically relevant laboratory values (hematology, clinical chemistry, coagulation, and urinalysis), • Physical examination, • Vital signs.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to next ascites puncture, number of ascites punctures until end of lifetime, overall survival, anti-cancer treatment</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>immune monitoring</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">230</enrollment>
  <condition>Cancer</condition>
  <condition>Neoplasms</condition>
  <condition>Carcinoma</condition>
  <condition>Malignant Ascites</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive premedication of 25 mg (i.v.) prednisolone 30 minutes prior start of infusion of catumaxomab.
Catumaxomab will be infused i.p. with 3 hour constant rate infusions via an indwelling catheter.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Catumaxomab will be administered in a dosage identical to Arm A but without the prednisolone premedication.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Catumaxomab</intervention_name>
    <description>Catumaxomab will be infused 4 times within 11 days as follows:
10 µg on day 0, 20 µg on day 3, 50 µg on day 7, 150 µg on day 10</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>25 mg premedication</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Patients with malignant ascites requiring therapeutic ascites puncture

          2. Histological confirmed diagnosis of epithelial cancer

          3. Patients where standard therapy is not available or no longer feasible

          4. Karnofsky index ≥60 %

          5. Life expectancy &gt;12 weeks

        Key Exclusion Criteria:

          1. Concomitant treatment with other investigational product, chemo-, or radiotherapy

          2. Recent exposure to an investigational product

          3. Known or suspected hypersensitivity to catumaxomab or similar antibodies

          4. Inadequate respiratory, renal or hepatic function

          5. Inadequate blood count (platelets, neutrophils)

          6. Required entirely parenteral nutrition

          7. Patients with ileus or subileus within the last 30 days

          8. Liver metastases with volume &gt;70 % of liver tissue

          9. Known portal vein obstruction

         10. Known Brain metastases

         11. Acute or chronic infection

         12. Not sufficiently recovered from previous treatment (toxicity present) based on
             laboratory values and general status

         13. Albumin lower than 3 g/dL or total protein &lt; 6g/dL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florian Lordick, PD Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Med. Klinik III, Städtisches Klinikum Braunschweig gGmbH, Celler STr. 38, 38114 Braunschweig</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Several</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study site</name>
      <address>
        <city>Several</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Several</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Several</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Lordick F, Ott K, Weitz J, Jäger D. The evolving role of catumaxomab in gastric cancer. Expert Opin Biol Ther. 2008 Sep;8(9):1407-15. doi: 10.1517/14712598.8.9.1407 . Review.</citation>
    <PMID>18694358</PMID>
  </reference>
  <reference>
    <citation>Burges A, Wimberger P, Kümper C, Gorbounova V, Sommer H, Schmalfeldt B, Pfisterer J, Lichinitser M, Makhson A, Moiseyenko V, Lahr A, Schulze E, Jäger M, Ströhlein MA, Heiss MM, Gottwald T, Lindhofer H, Kimmig R. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study. Clin Cancer Res. 2007 Jul 1;13(13):3899-905.</citation>
    <PMID>17606723</PMID>
  </reference>
  <reference>
    <citation>Shen J, Zhu Z. Catumaxomab, a rat/murine hybrid trifunctional bispecific monoclonal antibody for the treatment of cancer. Curr Opin Mol Ther. 2008 Jun;10(3):273-84.</citation>
    <PMID>18535935</PMID>
  </reference>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2008</study_first_submitted>
  <study_first_submitted_qc>January 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2009</study_first_posted>
  <last_update_submitted>October 2, 2012</last_update_submitted>
  <last_update_submitted_qc>October 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Carcinoma</keyword>
  <keyword>Malignant Ascites</keyword>
  <keyword>Drug therapy</keyword>
  <keyword>Antineoplastic Protocols</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Phase III</keyword>
  <keyword>trifunctional antibody</keyword>
  <keyword>monoclonal antibody</keyword>
  <keyword>EpCAM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascites</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Bispecific</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

